Differences in clinical characteristics and lesion proteomics between inflammatory linear verrucous epidermal nevus and local verrucous epidermal nevus

Yuan, Tao; Xiao‐hong, Lu; Tang, Biao; Chang, Xiaoli; He, Chun‐Xia; Wang, Jun; Ci, Chao

doi:10.1016/j.jprot.2022.104554

Cited by 4 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For epidermal nevi with inflammatory linear verrucous epidermal nevi (ILVEN) and verrucous epidermal nevi (VEN) with inflammation, an analysis using proteomics has been reported. According to the article of Yuan et al [3] , the upregulated proteins in ILVEN lesions relative to VEN lesions are mainly involved in neutrophil activation. On the other hand, the downregulated proteins are mainly involved in the cellular response to cytokine stimulation, cell adhesion, and Th1 and Th2 differentiation [3] .…”

Section: Discussionmentioning

confidence: 99%

“…According to the article of Yuan et al [3] , the upregulated proteins in ILVEN lesions relative to VEN lesions are mainly involved in neutrophil activation. On the other hand, the downregulated proteins are mainly involved in the cellular response to cytokine stimulation, cell adhesion, and Th1 and Th2 differentiation [3] . Our case is complicated by AD, which is expected to be associated with increased Th2 cytokines such as IL-4 and IL-13.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A case of unilateral epidermal nevi complicated by atopic dermatitis treated with dupilumab

Nagatsuka,

Nakashima,

Kitayama

et al. 2023

Trends Immunother.

View full text Add to dashboard Cite

Epidermal Nevus Syndrome (ENS) is a congenital disorder characterized by skin lesions called epidermal nevi. This condition typically appears at birth or in infancy. However, a case of adult‐onset epidermal nevi was reported in a 36‐year‐old male with a history of atopic dermatitis (AD) and skin abnormalities on the right side of his body. He had been using topical steroids for AD but eventually started dupilumab treatment at age 41. The treatment led to significant improvements in his skin condition, including a reduction in erythema and scaling. Laboratory tests also showed improvement in serum Immunoglobulin E (IgE) levels and other markers. We report with a literature review.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

A case of unilateral epidermal nevi complicated by atopic dermatitis treated with dupilumab

Nagatsuka,

Nakashima,

Kitayama

et al. 2023

Trends Immunother.

View full text Add to dashboard Cite

show abstract

“…1). Активный рост доброкачественных новообразований также может сопровождаться зудом, что описано, например, при врожденных меланоцитарных невусах [18], линейном веррукозном воспалительном эпидермальном невусе [19], эруптивных дерматофибромах [20], себорейном кератозе, включая паранеопластический синдром Лезера-Трела [21], при котором зуд сопровождает появление множественных себорейных кератом в 52% случаев.…”

Section: зуд ассоциированный с зноunclassified

Pruritus in cancer patients as a polyetiological symptom

Миченко

Lvov²,

Круглова³

et al. 2022

Consilium Medicum

View full text Add to dashboard Cite

Pruritus is one of the subjective sensations that significantly reduces the quality of life of patients. In patients with malignancies, itch can be caused by different universal or specific pathophysiological factors. This article discusses disorders that cause pruritus in cancer patients: the tumor growth on its own; pathophysiological changes associated with a number of malignancies, paraneoplastic itch, anticancer therapy, concomitant dermatoses, systemic diseases, psychosomatic disorders. Known or proposed mechanisms of the development of pruritus are presented for each of the mentioned provoking factors, and methods of treatment are described, according to the etiological factor. At the end of the article, universal methods for the correction of itching are presented, applicable in cancer patients, regardless of the pruritogenic factor. Special attention is paid to the correction of xerosis as a universal cause of itching in oncological patients.

show abstract